Gordon Lithgow received his PhD in Genetics from the University of Glasgow, Scotland. He completed postdoctoral training at the Institute for Behavioral Genetics at the University of Colorado, Boulder. Lithgow was a Senior Lecturer in Molecular Gerontology at the School of Biological Sciences at the University of Manchester in England before coming to the Buck Institute in 2001. He is the Principal Investigator and Director of the Buck Institute’s Interdisciplinary Research Consortium on Geroscience. He is also the Principal Investigator of the Larry L. Hillblom Network on the Chemical Biology of Aging, and is the Coordinator of the Hillblom Center for the Biology of Aging Support Award. Lithgow sheds light on the mechanisms of aging by identifying agents that extend lifespan or prevent age-related disease. He has discovered a range of factors that can lengthen life in the microscopic worm Caenorhabditis elegans, and he applies these findings to studies in human cell cultures. Much evidence points to stress contributing to a breakdown in the ability to maintain optimal molecular stability resulting in aging and disease. Certain life-extending agents help C. elegans respond to lifelong stress by remodeling the natural stress fighting cellular mechanisms, the Lithgow lab has found. The Lithgow lab has discovered that certain cell proteins capable of extending life can also be closely involved in disease prevention. But when proteins play such dual roles, they may sometimes make tradeoffs that affect the fate of the organism. Dr. Lithgow is studying genetic variations in “checkpoint proteins’’ that may create a trade-off between the rate of aging and incidence of cancer. His area of interest includes uncovering genes and small molecules that prolong lifespan through enhanced molecular stability.